DRI Healthcare Trust (TSE:DHT.UN) Reaches New 12-Month High – What’s Next?

Shares of DRI Healthcare Trust (TSE:DHT.UN) reached a new 52-week high during trading on Monday. The company traded as high as C$19.75 and last traded at C$19.67, with a volume of 24,523 shares trading hands. The stock had previously closed at C$19.23.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DHT.UN. Stifel Nicolaus boosted their target price on DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. National Bank Financial raised their price target on shares of DRI Healthcare Trust from C$23.50 to C$25.50 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of C$25.60.

DRI Healthcare Trust Trading Up 2.1%

The stock has a market capitalization of C$1.08 billion, a PE ratio of 18.19 and a beta of 0.09. The firm has a 50-day moving average price of C$17.99 and a 200-day moving average price of C$17.34.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.